Open-label, Multicenter Immunogenicity and Safety Study of MVA-BN Vaccine in Children from 2 Years to Less Than 12 Years of Age Compared to Adults for the Prevention of Smallpox, Mpox, and Related Orthopoxvirus Infections
Latest Information Update: 15 Jul 2025
At a glance
- Drugs Modified vaccinia Ankara (Primary)
- Indications Monkeypox; Orthopoxvirus infections; Smallpox
- Focus Adverse reactions; Pharmacodynamics; Registrational
- Sponsors Bavarian Nordic
Most Recent Events
- 26 Jun 2025 According to a Bavarian Nordic media release, topline results from this trial are anticipated in the Q3 2025.
- 29 Oct 2024 Status changed from not yet recruiting to recruiting, according to a Bavarian Nordic media release.
- 29 Oct 2024 According to a Bavarian Nordic media release, first children have now been vaccinated in the study, which is currently enrolling in the Democratic Republic of Congo (DRC) with plans also to include sites in Uganda.